Tasigna lawsuits filed in recent months have highlighted a growing body of scientific evidence linking the leukemia drug to arteriosclerosis, peripheral artery disease, and related vascular conditions.
For example, in 2011, the American Journal of Hematology published a study involving 24 patients who were taking Tasigna to treat chronic myelogenous leukemia (CML), 3 of whom went on to develop peripheral artery disease or other vascular disorders. You can find more information on wrongful death claims and atherosclerosis-related conditions, including stroke, heart attack a from tasignalawyer.com/.
When the cerebral walls have deciphered, peripheral vascular disease could lead to. Along with inducing degradation of the arterial walls, Tasigna also can induce illness, tissue departure requiring amputation, stroke, stroke, coronary heart disease and passing.
Novartis failed to reveal these records to U.S. health doctors or officials –after a warning has been issued by Canada’s medical bureau in 2013, concerning the risks of the medication. From the California wrongful death claimthe patient expired in 2014, by a huge stroke after his doctor switched him in Gleevec into Tasigna to cure his chronic myeloid leukemia. He’d no prior atherosclerosis-related states if he began taking Tasigna, but presently began showing symptoms of peripheral vascular disease after start Tasigna.
After taking the medication for around a yr, an angiogram revealed he was afflicted by 100 per cent blockage in his right femoral artery, and also a 90% blockage in the arteries behind both knees. At roughly precisely the exact same period, his physician happened up on a health journal article that made a match up between Tasigna and atherosclerosis-related states, also he had been removed the medication, but his cervical blockages were overly great, and he also expired in March 2014.
It seems that Canadian healthcare professionals and also the Canadian people were issued an advisory in April 2013, that cautioned of their atherosclerosis risks connected with Tasigna, actually according to Canadian advice sheets that accompanied Tasigna of their probability of potentially fatal atherosclerosis-related ailments. But those warnings never left it into the usa, and also the Tasigna tagging from the USA had no warnings.
The wrongful death claim alleges the failure to warn doctors and patients in the United States was intentional, and, in fact, was a part of an aggressive marketing strategy to have Tasigna outsell competing leukemia drugs. There have been numerous studies published over the years in medical journals which show that Tasigna could potentially cause irreversible, life-threatening conditions, resulting in limb amputation, cardiovascular issues and death, yet Novartis remained silent.